Thomas Burke

5.8k total citations · 1 hit paper
120 papers, 4.4k citations indexed

About

Thomas Burke is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Thomas Burke has authored 120 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 47 papers in Pulmonary and Respiratory Medicine and 35 papers in Surgery. Recurrent topics in Thomas Burke's work include Cancer Immunotherapy and Biomarkers (41 papers), Lung Cancer Treatments and Mutations (40 papers) and Lung Cancer Diagnosis and Treatment (21 papers). Thomas Burke is often cited by papers focused on Cancer Immunotherapy and Biomarkers (41 papers), Lung Cancer Treatments and Mutations (40 papers) and Lung Cancer Diagnosis and Treatment (21 papers). Thomas Burke collaborates with scholars based in United States, Spain and Germany. Thomas Burke's co-authors include Denise Dion, Sanjeev Arora, John Seely Brown, Paulina Deming, Clifford Qualls, Karla Thornton, Jeffrey C. Dunkelberg, Miriam Komaromy, Glen H. Murata and Steven M. Jenkusky and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Thomas Burke

116 papers receiving 4.2k citations

Hit Papers

Outcomes of Treatment for Hepatitis C Virus Infection by ... 2011 2026 2016 2021 2011 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers
    2011 789 citations Thomas Burke et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Burke United States 38 1.3k 1.2k 1.0k 596 523 120 4.4k
Lorraine L. Lipscombe Canada 44 1.1k 0.9× 1.3k 1.1× 382 0.4× 264 0.4× 809 1.5× 168 6.3k
Alaa Rostom Canada 32 2.3k 1.8× 1.5k 1.2× 1.3k 1.3× 929 1.6× 1.3k 2.4× 79 5.9k
Lorenza Scotti Italy 37 848 0.7× 1.1k 0.9× 594 0.6× 366 0.6× 1.1k 2.1× 113 4.9k
Linda L. Humphrey United States 24 568 0.5× 1.3k 1.1× 926 0.9× 147 0.2× 591 1.1× 44 5.4k
Mark H.H. Kramer Netherlands 42 1.5k 1.2× 356 0.3× 447 0.4× 359 0.6× 840 1.6× 154 5.8k
Laura E. Targownik Canada 44 2.5k 2.0× 791 0.7× 846 0.8× 313 0.5× 2.1k 4.0× 222 6.4k
Debra J. Jacobson United States 42 569 0.5× 400 0.3× 1.9k 1.9× 413 0.7× 843 1.6× 150 5.6k
Pierre Delanaye Belgium 46 727 0.6× 402 0.3× 1.1k 1.1× 178 0.3× 544 1.0× 289 7.7k
Spyridon S Marinopoulos Greece 23 783 0.6× 417 0.3× 279 0.3× 243 0.4× 590 1.1× 72 4.8k
Jacob A. Udell Canada 41 2.4k 1.9× 805 0.7× 756 0.7× 643 1.1× 1.1k 2.0× 165 8.8k

Countries citing papers authored by Thomas Burke

Since Specialization
Citations

This map shows the geographic impact of Thomas Burke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Burke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Burke more than expected).

Fields of papers citing papers by Thomas Burke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Burke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Burke. The network helps show where Thomas Burke may publish in the future.

Co-authorship network of co-authors of Thomas Burke

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Burke. A scholar is included among the top collaborators of Thomas Burke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Burke. Thomas Burke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schmalz, Oliver, Thomas Burke, Josephine M. Norquist, et al.. (2023). MT53 Remote Symptom Monitoring for Lung Cancer Patients: Lessons Learned from the Lung Aid Study. Value in Health. 26(12). S436–S437.
2.
Massa, Ilaria, Flavia Foca, Angelo Delmonte, et al.. (2022). Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. Cancers. 14(18). 4481–4481. 4 indexed citations
3.
4.
Arunachalam, Ashwini, et al.. (2021). Real-World Study of PD-L1 Testing Patterns and Treatment Distribution in Patients with Metastatic Non-Small-Cell Lung Cancer in Israel. Immunotherapy. 13(10). 851–861. 3 indexed citations
5.
Jemielita, Thomas, Xiaoyun Li, Thomas Burke, et al.. (2021). Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non–small-Cell Lung Cancer Treated With Pembrolizumab. JCO Clinical Cancer Informatics. 5(5). 849–858. 2 indexed citations
6.
Ejzykowicz, Flavia, Xiaohan Chen, Allison Petrilla, et al.. (2020). PCN19 PATIENT CHARACTERISTICS AND FIRST LINE TREATMENTS AMONG MEDICARE PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC). Value in Health. 23. S25–S25. 1 indexed citations
7.
8.
Williams, Loretta A., Qiuling Shi, Seyedeh Dibaj, et al.. (2019). MA19.03 Differences in Symptom Burden Between Responsive and Progressive Disease in Advanced Non-Small Cell Lung Cancer (aNSCLC). Journal of Thoracic Oncology. 14(10). S327–S327. 1 indexed citations
9.
Chandwani, Sheenu, et al.. (2019). P2.16-41 Pembrolizumab for Previously Treated, PD-L1–Expressing Advanced NSCLC: Real-World Time on Treatment and Overall Survival. Journal of Thoracic Oncology. 14(10). S882–S882. 1 indexed citations
10.
Williams, Loretta A., Shiva Dibaj, Sheenu Chandwani, et al.. (2018). P3.01-109 Real-World Patient-Reported Outcome Assessment of Patients with Metastatic Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S907–S908. 1 indexed citations
11.
Garassino, Marina Chiara, Delvys Rodríguez‐Abreu, S. Gadgeel, et al.. (2018). PD.1.01 Health-Related Quality of Life with Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189. Journal of Thoracic Oncology. 13(9). S155–S155. 1 indexed citations
12.
Mazières, Julien, Dariusz M. Kowalski, Alexander Luft, et al.. (2018). Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407. Annals of Oncology. 29. viii748–viii749. 2 indexed citations
13.
Huang, Mo, et al.. (2016). Cost-Effectiveness of Pembrolizumab vs. Docetaxel for Treatment of Previously Treated PD-l1 Positive Advanced NSCLC Patients. Value in Health. 19(7). A737–A737. 3 indexed citations
14.
Keefe, Dorothy, Alexandre Chan, Hoon-Kyo Kim, et al.. (2014). Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study. Supportive Care in Cancer. 23(1). 253–261. 7 indexed citations
15.
Lopes, Gilberto, et al.. (2012). Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore. Value in Health Regional Issues. 1(1). 66–74. 10 indexed citations
16.
Leahy, Michael, Xavier García del Muro, Peter Reichardt, et al.. (2012). Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study. Annals of Oncology. 23(10). 2763–2770. 56 indexed citations
17.
Burke, Thomas, Miriam Sturkenboom, Pamela Ohman‐Strickland, Charles Wentworth, & George G. Rhoads. (2007). The effect of antihypertensive drugs and drug combinations on the incidence of new‐onset type‐2 diabetes mellitus. Pharmacoepidemiology and Drug Safety. 16(9). 979–987. 16 indexed citations
18.
Vicente-Herrero, Teófila, Thomas Burke, & Miguel J. A. Láinez. (2004). The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective. Current Medical Research and Opinion. 20(11). 1805–1814. 40 indexed citations
19.
Morant, S. V., et al.. (2004). Application of a propensity score to adjust for channelling bias with NSAIDs. Pharmacoepidemiology and Drug Safety. 13(6). 345–353. 12 indexed citations
20.
Zhao, Sean Z., et al.. (2002). Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.. PubMed. 8(15 Suppl). S401–13. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lorraine L. Lipscombe Breakdown of academic impact, for papers by Alaa Rostom Breakdown of academic impact, for papers by Lorenza Scotti Breakdown of academic impact, for papers by Linda L. Humphrey Breakdown of academic impact, for papers by Mark H.H. Kramer Breakdown of academic impact, for papers by Laura E. Targownik Breakdown of academic impact, for papers by Debra J. Jacobson Breakdown of academic impact, for papers by Pierre Delanaye Breakdown of academic impact, for papers by Spyridon S Marinopoulos Breakdown of academic impact, for papers by Jacob A. Udell
Rankless by CCL
2026